HARBIN GLORIA PHARMACEUTICALS CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.14 CNY | +2.39% |
|
+7.54% | -14.74% |
| Sales 2022 | 3.11B 430M 587M | Sales 2023 | 2.63B 363M 496M | Capitalization | 5.52B 763M 1.04B |
|---|---|---|---|---|---|
| Net income 2022 | -291M -40.24M -54.93M | Net income 2023 | 120M 16.59M 22.65M | EV / Sales 2022 | 1.85 x |
| Net Debt 2022 | 167M 23.05M 31.46M | Net cash position 2023 | 35.59M 4.92M 6.72M | EV / Sales 2023 | 2.09 x |
| P/E ratio 2022 |
-19.2
x | P/E ratio 2023 |
45.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.71% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.39% | ||
| 1 week | +7.54% | ||
| 1 month | +0.47% | ||
| 3 months | -6.55% | ||
| 6 months | -11.93% | ||
| Current year | -14.74% |
1 week
1.97
2.15
1 month
1.912.20
Current year
1.672.64
1 year
1.673.15
3 years
1.673.40
5 years
1.674.88
10 years
1.6715.11
| Managers | Title | Age | Since |
|---|---|---|---|
Lei Feng Guo
CEO | Chief Executive Officer | 51 | 22-11-10 |
Zuo Zhe Ji
DFI | Director of Finance/CFO | 47 | 20-12-17 |
Jia Feng Zang
CTO | Chief Tech/Sci/R&D Officer | 48 | 21-04-26 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin Hu
CHM | Chairman | 48 | 20-07-21 |
Min Pan
BRD | Director/Board Member | 53 | 22-12-19 |
Xiu Qiang Diao
BRD | Director/Board Member | 47 | 12-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-28 | 2.14 | +2.39% | 43 927 800 |
| 24-04-26 | 2.09 | +1.95% | 33,836,500 |
| 24-04-25 | 2.05 | +1.49% | 36,301,550 |
| 24-04-24 | 2.02 | +0.50% | 21,753,700 |
| 24-04-23 | 2.01 | +1.01% | 30,694,790 |
End-of-day quote Shenzhen S.E., April 28, 2024
More quotes
HARBIN GLORIA PHARMACEUTICALS Co., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The Company is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-10
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -14.74% | 655M | |
| +20.81% | 43.34B | |
| +20.44% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002437 Stock
